Japan targets 'faster than US FDA' medtech approvals, but reimbursement remains a problem
This article was originally published in SRA
Executive Summary
Japanese medical device regulatory conditions are improving fast, at least, that is the intention behind recent ground breaking medtech-specific legislation and a new five-year plan to speed device approvals. But device reimbursement levels remain in need of attention, says Philip Agress, senior vice-president of global strategy and analysis at US medtech industry association AdvaMed.
You may also be interested in...
Post-Brexit MHRA Will Embrace Medtech ‘Innovation Pull’ In The UK
The national regulator is to undergo a review in 2021 as the UK begins life as a former EU member, presenting opportunities to be seized.
Advancing The Precision Mission At RSNA 2020
RSNA is the next major global medtech event to be run under a virtual format this fall. Under COVID-19, the major medtechs are finding different ways to demonstrate value, as Royal Philips explains.
Advancing The Precision Mission At RSNA 2020
The RSNA is the next global medtech exhibition and conference event to be run under a virtual format this fall.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: